RSK Activation of Translation Factor eIF4B Drives Abnormal Increases of Laminin γ2 and MYC Protein during Neoplastic Progression to Squamous Cell Carcinoma

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Degen, Martin ^a   Barron, Patricia ^a   Natarajan, Easwar ^b   Widlund, Hans R ^a   Rheinwald, James G ^a  

^a Harvard Skin Disease Research Center   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4B; LAMININ GAMMA2; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN E6; PROTEIN S6; S6 KINASE; TUMOR PROTEIN; UNCLASSIFIED DRUG; EIF-4B; INITIATION FACTOR; LAMC2 PROTEIN, HUMAN; LAMININ;

5' UNTRANSLATED REGION; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; ELF4B GENE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KERATINOCYTE; LAMININ GAMMA2 GENE; MOLECULAR MODEL; MOUTH MALFORMATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA SEQUENCE; RNA TRANSLATION; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEK293 CELL LINE; METABOLISM; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; EUKARYOTIC INITIATION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; LAMININ; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; NEOPLASTIC PROCESSES; RNA, MESSENGER;

EID: 84886606822     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078979     Document Type: Article

References (54)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Leemans CR, Braakhuis BJ, Brakenhoff RH, (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9-22.
3. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, et al. (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157-1160.
4. Klein JD, Grandis JR, (2010) The molecular pathogenesis of head and neck cancer. Cancer Biol Ther 9: 1-7.
5. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, et al. (2009) Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 45: 324-334.
6. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, et al. (2006) Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 31: 259-266.
7. Lingen MW, Xiao W, Schmidt A, Jiang B, Pickard R, et al. (2012) Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol.
8. Syrjanen S, (2005) Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 32Suppl 1: S59-66.
9. Argiris A, Karamouzis MV, Raben D, Ferris RL, (2008) Head and neck cancer. Lancet 371: 1695-1709.
10. Chen LF, Cohen EE, Grandis JR, (2010) New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 16: 2489-2495.
11. Chen SJ, Nakahara T, Takahara M, Kido M, Dugu L, et al. (2009) Activation of the mammalian target of rapamycin signaling pathway in epidermal tumours and its correlation with cyclin-dependent kinase 2. Br J Dermatol 160: 442-445.
12. Napier SS, Speight PM, (2008) Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med 37: 1-10.
13. Bremmer JF, Brakenhoff RH, Broeckaert MA, Belien JA, Leemans CR, et al. (2011) Prognostic value of DNA ploidy status in patients with oral leukoplakia. Oral Oncol 47: 956-960.
14. Holmstrup P, Vedtofte P, Reibel J, Stoltze K, (2006) Long-term treatment outcome of oral premalignant lesions. Oral Oncol 42: 461-474.
15. van der Waal I, (2009) Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol 45: 317-323.
16. Koshikawa N, Moriyama K, Takamura H, Mizushima H, Nagashima Y, et al. (1999) Overexpression of laminin γ2 chain monomer in invading gastric carcinoma cells. Cancer Res 59: 5596-5601.
17. Ono Y, Nakanishi Y, Ino Y, Niki T, Yamada T, et al. (1999) Clinocopathologic significance of laminin-5 γ2 chain expression in squamous cell carcinoma of the tongue: immunohistochemical analysis of 67 lesions. Cancer 85: 2315-2321.
18. Pyke C, Romer J, Kallunki P, Lund LR, Ralfkiaer E, et al. (1994) The γ2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol 145: 782-791.
19. Natarajan E, Saeb M, Crum CP, Woo SB, McKee PH, et al. (2003) Co-expression of p16INK4A and laminin 5 γ2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am J Pathol 163: 477-491.
20. Nordemar S, Hogmo A, Lindholm J, Auer G, Munck-Wikland E, (2003) Laminin-5 γ2: a marker to identify oral mucosal lesions at risk for tumor development? Anticancer Res 23: 4985-4989.
21. Degen M, Natarajan E, Barron P, Widlund HR, Rheinwald JG, (2012) MAPK/ERK-dependent translation factor hyperactivation and dysregulated Laminin γ2 expression in oral dysplasia and squamous cell carcinoma. Am J Pathol 180: 2462-2478.
22. Lawson TG, Lee KA, Maimone MM, Abramson RD, Dever TE, et al. (1989) Dissociation of double-stranded polynucleotide helical structures by eukaryotic initiation factors, as revealed by a novel assay. Biochemistry 28: 4729-4734.
23. Rogers GW Jr, Richter NJ, Lima WF, Merrick WC, (2001) Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F. J Biol Chem 276: 30914-30922.
24. Rozen F, Edery I, Meerovitch K, Dever TE, Merrick WC, et al. (1990) Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A and 4F. Mol Cell Biol 10: 1134-1144.
25. Shahbazian D, Parsyan A, Petroulakis E, Hershey J, Sonenberg N, (2010) eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle 9: 4106-4109.
26. Shahbazian D, Parsyan A, Petroulakis E, Topisirovic I, Martineau Y, et al. (2010) Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol Cell Biol 30: 1478-1485.
27. Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, et al. (2000) Human keratinocytes that express hTERT and also bypass a p16INK4A-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 20: 1436-1447.
28. Natarajan E, Omobono JD 2nd, Guo Z, Hopkinson S, Lazar AJ, et al. (2006) A keratinocyte hypermotility/growth-arrest response involving Laminin 5 and p16INK4A activated in wound healing and senescence. Am J Pathol 168: 1821-1837.
29. Rheinwald JG, Beckett MA, (1980) Defective terminal differentiation in culture as a consistent and selectable character of malignant human keratinocytes. Cell 22: 629-632.
30. Dabelsteen S, Hercule P, Barron P, Rice M, Dorsainville G, et al. (2009) Epithelial cells derived from human embryonic stem cells display p16INK4A senescence, hypermotility, and differentiation properties shared by many p63+ somatic cell types. Stem Cells 27: 1388-1399.
31. Foster SA, Demers GW, Etscheid BG, Galloway DA, (1994) The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol 68: 5698-5705.
32. Mietz JA, Unger T, Huibregtse JM, Howley PM, (1992) The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. Embo J 11: 5013-5020.
33. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, et al. (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7: 379-387.
34. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, et al. (2005) Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med 2: e313.
35. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, et al. (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754.
36. Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, et al. (2007) BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J 401: 29-38.
37. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632.
38. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N, (2010) Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 1804: 433-439.
39. Garcia-Martinez JM, Moran J, Clarke RG, Gray A, Cosulich SC, et al. (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 421: 29-42.
40. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, et al. (2006) A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125: 733-747.
41. Mizushima H, Koshikawa N, Moriyama K, Takamura H, Nagashima Y, et al. (1998) Wide distribution of laminin-5 γ2 chain in basement membranes of various human tissues. Horm Res 50Suppl 2: 7-14.
42. Venkatesan A, Sharma R, Dasgupta A, (2003) Cell cycle regulation of hepatitis C and encephalomyocarditis virus internal ribosome entry site-mediated translation in human embryonic kidney 293 cells. Virus Res 94: 85-95.
43. Pinto AP, Degen M, Barron P, Crum CP, Rheinwald JG (2013) Phosphorylated S6 as an immunohistochemical biomarker of vulvar intraepithelial neoplasia. Mod Pathol (in press).
44. Spangle JM, Munger K, (2010) The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol 84: 9398-9407.
45. Gingras AC, Raught B, Sonenberg N, (1999) eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68: 913-963.
46. McLaughlin-Drubin ME, Munger K, (2009) Oncogenic activities of human papillomaviruses. Virus Res 143: 195-208.
47. Ferrari S, Bandi HR, Hofsteenge J, Bussian BM, Thomas G, (1991) Mitogen-activated 70K S6 kinase. Identification of in vitro 40 S ribosomal S6 phosphorylation sites. J Biol Chem 266: 22770-22775.
48. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, et al. (2004) S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24: 3112-3124.
49. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, et al. (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282: 14056-14064.
50. Castellano E, Downward J, (2011) RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2: 261-274.
51. Inoki K, Zhu T, Guan KL, (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
52. Bordeleau ME, Mori A, Oberer M, Lindqvist L, Chard LS, et al. (2006) Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat Chem Biol 2: 213-220.
53. Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R, et al. (2009) Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One 4: e5223.
54. Jin C, Rajabi H, Rodrigo CM, Porco JA Jr, Kufe D, (2012) Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene 32: 2179-2188.